Ask AI
Back Back
PBC First Line Treatment
Assessing UDCA Intolerance and Response in PBC: First-line Treatment Questions

Released: March 13, 2026

Sonal Kumar
Sonal Kumar, MD, MPH
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • UDCA intolerance requires dose timing adjustment or a shift to second-line treatment.
  • The new PBC treatment paradigm is a 6-month assessment of treatment response in patients with risk factors for UDCA failure and disease progression.

The first-line treatment for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA), is usually well tolerated. However, up to 5% of patients are intolerant, with symptoms including diarrhea, nausea, hair loss, and skin rashes.

The first step to address UDCA intolerance is determining if it can be managed with adjustments to timing of doses to alleviate side effects. For example, if the patient is reporting gastrointestinal symptoms, you can suggest taking it with meals to see if symptoms improve. In patients who I think are at higher risk of having gastrointestinal side effects, to help prevent intolerance and prevent self-discontinuation of the medication, I sometimes start with 1 dose of UDCA per day, then have them titrate up to 2 doses to the recommended full weight-based dose.

In my practice, hair loss is the most common complaint I get from patients, though I will say it is still rare. Unfortunately, hair loss is not typically relieved by adjusting dose timing or taking UDCA with food.

If a patient is experiencing side effects that they find intolerable and they are unable to continue UDCA, I will switch them to a peroxisome proliferator–activated receptor (PPAR) agonist. PPARs are well tolerated and work well. They have evidence for improving alkaline phosphatase (ALP) and are specifically indicated as monotherapy for people who cannot tolerate UDCA or as add-on therapy for people with inadequate response to UDCA.

Early Assessment
Key ways that the paradigm of PBC management is changing are earlier assessment of treatment response and greater individualization of treatment. Although guidelines recommend waiting 12 months to assess response to UDCA, there is a movement to assess earlier, at 6 months, depending on patient-specific risk factors for severe disease.

For example, for a 70-year-old patient with PBC who has no fibrosis, I would start UDCA and wait 12 months to assess the treatment response. If at 12 months, she has achieved ALP <1.67 times the upper limit of normal, I am probably not going to start her on second-line therapy because she is not at high risk for poor outcomes.

However, for a 45-year-old patient, I will assess treatment response to UDCA at 6 months, regardless of whether they have fibrosis, because I consider their young age to be a risk factor for disease progression. Response to UDCA usually occurs within the first 6 months of therapy, so by then I have an idea if a patient will end up needing second-line therapy. In patients who have any risk factors for disease progression, such as young age or advanced fibrosis on noninvasive tests, I will assess the need for second-line therapy at 6 months instead of waiting until 1 year.

Symptoms are so common in PBC, and now second-line therapy with PPAR agonists has shown they can improve itching and may also improve other symptoms, such as fatigue.  So sometimes, symptoms of pruritus or fatigue will push me to try second-line therapy. However, I also want to ensure that second-line treatment is not initiated prematurely or unnecessarily. I do not assess UDCA treatment response before 6 months to be certain that there is sufficient time for UDCA to work. And it’s important to understand that although the PPAR agonists can help with symptoms, they are not indicated to treat symptoms, so I won’t use them in patients who achieve a biochemical response with UDCA alone.  

The guidelines have not yet caught up to this clinical practice, but when the guidelines are updated, I think they will shift to more individualized care where we take into account patient-specific risk factors and symptoms. I hope they will highlight how patients who are at high risk for disease progression and treatment failure should be assessed at 6 months instead of 12 months. I also think they will move toward ALP normalization, not just improvement, as the end goal of treatment.

Your Thoughts
How do you manage intolerance to UDCA in your practice? What challenges are you currently experiencing with assessing first-line treatment response? Leave a comment to join the discussion!

Continue